Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich. , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Toggle Summary Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
ANN ARBOR, Mich. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Toggle Summary Esperion to Host Analyst and Investor Day Event on July 10
ANN ARBOR, Mich. , July 03, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Toggle Summary Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
— Simultaneous Presentation of Full Data from 1 st Phase 3 Study at ISA and Publication in the Journal Atherosclerosis — ANN ARBOR, Mich., June 12, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the full Phase 3 results from Study 4 (1002-048, also known as CLEAR Tranquility)
Toggle Summary Esperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
ANN ARBOR, Mich., May 30, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol